FDA Grants Talquetamab Accelerated Approval for R/R Multiple Myeloma
Patients with relapsed/refractory multiple myeloma may now receive talquetamab following the agent’s accelerated approval by the FDA.
Stay updated with breaking news from Fda Approval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients with relapsed/refractory multiple myeloma may now receive talquetamab following the agent’s accelerated approval by the FDA.
Dana Chase, MD, FACOG, discusses key efficacy, safety, and quality of life data from the RUBY trial supporting the FDA approval of dostarlimab and explains how this approval could help improve the efficacy of current chemotherapy regimens in advanced-stage or recurrent endometrial cancer.
/PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has received 510(k) clearance from the U.S. Food and Drug Administration...
/PRNewswire/ -- Astellas Pharma US, Inc. (President: Mark Reisenauer, "Astellas") announced that the U.S. Food and Drug Administration (FDA) has accepted the...
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted...